All In Biotech

Drug Trial Radar · NCT05491733

A Bioequivalence Study of APX001 High-load and Low-load Tablets

A 3-Treatment, 3-Period, 6-Sequence Randomized Crossover Single-Dose Study Evaluating the Bioequivalence of High-Load and Low-Load Oral Tablet Formulations of Apx001 and the Effect of Food on the Absorption of Apx001 From the High-Load Tablet In Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Mar 2, 2021

Primary completion

May 13, 2021

Study completion Jun 23, 2021

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Aug 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.

Conditions

  • Invasive Fungal Infections

Interventions

  • APX001Drug

    Low-load oral tablet

  • APX001ADrug

    High-load oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  5. Area Under the Curve From Time Zero to 24 hours (AUC0-24)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  6. Percentage of Area Under the Curve Extrapolated to Infinity (%AUCextra)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  7. Plasma Decay Half-Life (t1/2)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  8. Apparent Terminal Elimination Rate Constant (λz)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  9. Apparent Total clearance, Calculated as Dose/AUCinf (CL/F)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  10. Apparent Volume of Distribution at Terminal Phase (Vz/F)Time frame: Predose, 0.5, 1, 2, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 168, and 312 hours post dose
  11. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Time frame: Baseline through Day 14
  12. Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline through Day 14
  13. Number of Participants With Clinically Significant Change in Vital SignsTime frame: Baseline through Day 14
  14. Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG) AbnormalitiesTime frame: Baseline through Day 14
  15. Number of Participants With Abnormalities in Physical ExaminationsTime frame: Baseline through Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaceuticals Research Associates, Inc

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.